Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063193 · ClinicalTrials.gov registry record · Phase 2
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
A Phase 2 study of Parkinson's Disease, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
- 1
- Study location
NCT00063193: Completed Phase 2 study of Parkinson's Disease, sponsored by University of Rochester.
NCT00063193 is a Phase 2 study of Parkinson's Disease that has completed, run by University of Rochester. The registered enrollment target is 195 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063193, a Phase 2 study of Parkinson's Disease, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess the impact of minocycline and creatine on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
Conditions Studied
Interventions
- DRUG minocycline
- DRUG creatine
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00063193 record still lists
NCT00063193 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which minocycline is the first listed.
NCT00063193 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00063193 about?
NCT00063193 is a clinical study titled "National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial". The goal of this study is to assess the impact of minocycline and creatine on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.
What is the current status of trial NCT00063193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2003-05. Estimated completion is 2005-07.
What conditions does trial NCT00063193 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00063193?
The interventions under investigation include: minocycline (DRUG), creatine (DRUG).
Who is sponsoring clinical trial NCT00063193?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00063193 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00063193's enrollment target sits among peer trials
195 35th of 158 higher than 124 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia